Stosowanie rasagiliny w połączeniu z lewodopą w terapii choroby Parkinsona Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2018
Słowa kluczowe:
rasagilina, choroba Parkinsona, terapia dodana
##plugins.themes.bootstrap3.article.main##
Abstrakt
Rasagilina jest nieodwracalnym, selektywnym inhibitorem MAO-B drugiej generacji. Jej skuteczność w terapii dodanej do lewodopy w zaawansowanej chorobie Parkinsona (ChP) została potwierdzona w badaniach randomizowanych. Rasagilina jest dobrze tolerowana, nawet przez pacjentów przyjmujących wiele innych leków. W terapii dodanej do lewodopy rasagilina zmniejsza czas stanów OFF u chorych doświadczających fluktuacji oraz poprawia główne objawy ruchowe zaawansowanej ChP.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gorzkowska , A. (2018). Stosowanie rasagiliny w połączeniu z lewodopą w terapii choroby Parkinsona . Medycyna Faktów , 11(4(41), 333-336. https://doi.org/10.24292/01.MF.0418.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Rabey J.M., Sagi I., Huberman M. et al.; Rasagiline Study Group: Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol. 2000; 23: 324-330.
2. Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO Study. Arch. Neurol. 2005; 62: 241-248.
3. Rascol O., Brooks D.J., Melamed E. et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954.
4. Lew M.F.: Rasagiline treatment effects on parkinsonian tremor. Int. J. Neurosci. 2013; 123: 859-865.
5. Masselis M., Collinson S., Freeman N. et al.: Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 2016; 139(Pt 7): 2050-2062.
6. Cibulcik F., Benetin J., Kurca E.: Effects of rasagiline on freezing of gait in Parkinson’s disease – an open-label, multicenter study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub. 2016; 160(4): 549-552.
7. Lim T.T., Kluger B.M., Rodriguez R.L. et al.: Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov. Disord. 2015; 30: 1825-1830.
8. Schettino C., Dato C., Capaldo G. et al.: Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study. Neuropsychiatr. Dis. Treat. 2016; 12: 2497-2502.
9. Reichmann H., Jost W.: Efficacy and tolerability of rasagilline in daily clinical use – a post-marketing, observational study in patients with Parkinson’s disease. Eur. J. Neurol. 2010: 17: 1164-1171.
10. Ferreira J.J., Katzenschlager R., Bloem B.R. et al.: Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 2013; 20: 5-15.
2. Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO Study. Arch. Neurol. 2005; 62: 241-248.
3. Rascol O., Brooks D.J., Melamed E. et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954.
4. Lew M.F.: Rasagiline treatment effects on parkinsonian tremor. Int. J. Neurosci. 2013; 123: 859-865.
5. Masselis M., Collinson S., Freeman N. et al.: Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 2016; 139(Pt 7): 2050-2062.
6. Cibulcik F., Benetin J., Kurca E.: Effects of rasagiline on freezing of gait in Parkinson’s disease – an open-label, multicenter study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub. 2016; 160(4): 549-552.
7. Lim T.T., Kluger B.M., Rodriguez R.L. et al.: Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov. Disord. 2015; 30: 1825-1830.
8. Schettino C., Dato C., Capaldo G. et al.: Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study. Neuropsychiatr. Dis. Treat. 2016; 12: 2497-2502.
9. Reichmann H., Jost W.: Efficacy and tolerability of rasagilline in daily clinical use – a post-marketing, observational study in patients with Parkinson’s disease. Eur. J. Neurol. 2010: 17: 1164-1171.
10. Ferreira J.J., Katzenschlager R., Bloem B.R. et al.: Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 2013; 20: 5-15.